Roche NP28673: Phase I/II Trial of RO54248002 in NSCLC Patients

• Research type

  Research Study

• Full title

  AN OPEN-LABEL, NON-RANDOMIZED, MULTICENTER PHASE I/II TRIAL OF RO5424802 GIVEN ORALLY TO NON-SMALL CELL LUNG CANCER PATIENTS WHO HAVE ALK MUTATION AND FAILED CRIZOTINIB TREATMENT

• IRAS ID

  126536

• Contact name

  Marianne Nicolson

• Contact email

  mnicolson@nhs.net

• Sponsor organisation

  Roche

• Eudract number

  2012-004455-36

• REC name

  Scotland A REC

• REC reference

  13/SS/0071

• Date of REC Opinion

  2 Jul 2013

• REC opinion

  Further Information Favourable Opinion